PL2057156T3 - Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR - Google Patents

Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR

Info

Publication number
PL2057156T3
PL2057156T3 PL07789277T PL07789277T PL2057156T3 PL 2057156 T3 PL2057156 T3 PL 2057156T3 PL 07789277 T PL07789277 T PL 07789277T PL 07789277 T PL07789277 T PL 07789277T PL 2057156 T3 PL2057156 T3 PL 2057156T3
Authority
PL
Poland
Prior art keywords
pyrazo
pyrimido
pyrido
methylmorpholine
pyrimidine derivatives
Prior art date
Application number
PL07789277T
Other languages
English (en)
Inventor
Heather Mary Ellen Duggan
Frederic Georges Marie Leroux
Karine Malagu
Niall Morrisson Barr Martin
Keith Allan Menear
Graeme Cameron Murray Smith
Original Assignee
Kudos Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38537521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2057156(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kudos Pharmaceuticals Limited filed Critical Kudos Pharmaceuticals Limited
Publication of PL2057156T3 publication Critical patent/PL2057156T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07789277T 2006-08-23 2007-08-21 Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR PL2057156T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82331106P 2006-08-23 2006-08-23
US93877607P 2007-05-18 2007-05-18

Publications (1)

Publication Number Publication Date
PL2057156T3 true PL2057156T3 (pl) 2017-08-31

Family

ID=38537521

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07789277T PL2057156T3 (pl) 2006-08-23 2007-08-21 Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR

Country Status (29)

Country Link
US (6) US7902189B2 (pl)
EP (1) EP2057156B1 (pl)
JP (2) JP5227321B2 (pl)
KR (1) KR101438245B1 (pl)
AR (1) AR062503A1 (pl)
AU (1) AU2007287430B2 (pl)
BR (1) BRPI0715888B1 (pl)
CA (1) CA2659851C (pl)
CL (1) CL2007002448A1 (pl)
CO (1) CO6150164A2 (pl)
CY (1) CY1119381T1 (pl)
DK (1) DK2057156T3 (pl)
ES (1) ES2648388T3 (pl)
HR (1) HRP20170627T1 (pl)
HU (1) HUE033894T2 (pl)
IL (1) IL196775A (pl)
LT (1) LT2057156T (pl)
MX (1) MX2009001946A (pl)
MY (1) MY148688A (pl)
NO (1) NO342383B1 (pl)
NZ (1) NZ575672A (pl)
PL (1) PL2057156T3 (pl)
PT (1) PT2057156T (pl)
RS (1) RS55881B1 (pl)
RU (1) RU2445312C2 (pl)
SA (1) SA07280461B1 (pl)
SI (1) SI2057156T1 (pl)
TW (1) TWI406863B (pl)
WO (1) WO2008023161A1 (pl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69638122D1 (de) * 1996-09-04 2010-03-18 Intertrust Tech Corp Zuverlässige Infrastrukturhilfssysteme, Verfahren und Techniken für sicheren elektronischen Handel, elektronische Transaktionen, Handelsablaufsteuerung und Automatisierung, verteilte Verarbeitung und Rechteverwaltung
RS55881B1 (sr) * 2006-08-23 2017-08-31 Kudos Pharm Ltd 2-metilmorfolin pirido-,pirazo- i pirimido-pirimidin derivati kao inhibitori mtor-a
KR20100089082A (ko) * 2007-10-15 2010-08-11 아스트라제네카 아베 조합 059
AU2009215375A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
PE20110147A1 (es) * 2008-06-20 2011-03-26 Astrazeneca Ab Composicion y proceso - 356
AR073354A1 (es) * 2008-07-31 2010-11-03 Genentech Inc Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
PT2308877E (pt) 2008-08-05 2014-05-02 Daiichi Sankyo Co Ltd Derivados de imidazopiridin-2-ona
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
EP2362775B1 (en) * 2008-11-20 2015-08-05 GlaxoSmithKline LLC Chemical compounds
CA2751501C (en) * 2009-02-12 2018-01-16 Merck Serono S.A. 2-morpholino-pyrido[3,2-d]pyrimidines
US20120114637A1 (en) * 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
EP2445346A4 (en) * 2009-06-24 2012-12-05 Genentech Inc OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
RU2607635C2 (ru) 2009-11-12 2017-01-10 Ф.Хоффманн-Ля Рош Аг N-9-замещенные пуриновые соединения, композиции и способы применения
KR101447789B1 (ko) 2009-11-12 2014-10-06 에프. 호프만-라 로슈 아게 Ｎ-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법
NZ599964A (en) 2009-11-18 2014-08-29 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
WO2011067356A2 (en) 2009-12-03 2011-06-09 Novartis Ag Polymorphs of a mek inhibitor
WO2011067348A2 (en) 2009-12-03 2011-06-09 Novartis Ag Mek inhibitor salts and solvates thereof
EP2531194B1 (en) 2010-02-03 2018-04-18 Signal Pharmaceuticals, LLC Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
RU2012146083A (ru) 2010-03-30 2014-05-10 Новартис Аг Ингибиторы ркс для лечения в-клеточной лимфомы с хроническими активным сигнальным каскадом в-клеточного рецептора
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
WO2011161216A1 (en) 2010-06-25 2011-12-29 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
BR112013014914B8 (pt) 2010-12-16 2020-08-04 Hoffmann La Roche composto, composição farmacêutica e uso de um composto
WO2013003801A2 (en) 2011-06-29 2013-01-03 The Trustees Of Columbia University In The City Of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
WO2013019927A1 (en) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
CA2868392A1 (en) 2012-05-23 2013-11-28 Estelle DOUDEMENT Compositions and methods of obtaining and using endoderm and hepatocyte cells
JP6535430B2 (ja) * 2012-09-28 2019-06-26 イグニタ、インク． 非定型プロテインキナーゼｃのアザキナゾリン阻害薬
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
BR112015017331B1 (pt) 2013-01-23 2022-01-11 Astrazeneca Ab Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição
EP2968317A4 (en) * 2013-03-15 2016-12-28 Univ Columbia TARGETING OF THE MTOR PATH IN NEUROLOGICAL DISEASES
KR102221005B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법
JP6382948B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
AU2014254053B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with Dihydropyrazino-Pyrazines
NZ730189A (en) 2013-04-17 2018-09-28 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
KR102271344B1 (ko) 2013-04-17 2021-07-01 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
EP3360875A1 (en) 2013-05-28 2018-08-15 Astrazeneca AB Chemical compounds
WO2014193912A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
WO2017031427A1 (en) * 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
WO2017106607A1 (en) * 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
WO2017182495A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
TW201815789A (zh) 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
JP7348071B2 (ja) 2017-05-02 2023-09-20 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤としてのラパマイシン類似体
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
BR112020008991A2 (pt) 2017-11-06 2020-11-17 Medshine Discovery Inc. compostos de piridopirimidina que atuam como inibidores duais de mtorc 1/2
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2019170543A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
US11471459B2 (en) 2018-03-26 2022-10-18 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) Compounds with enhanced anti-tumor effects
CN112368289B (zh) 2018-05-01 2024-02-20 锐新医药公司 作为mtor抑制剂的c26-连接的雷帕霉素类似物
CR20200578A (es) 2018-05-01 2021-02-22 Revolution Medicines Inc Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
EP3877511A1 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
WO2020147842A1 (zh) * 2019-01-18 2020-07-23 南京明德新药研发有限公司 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
JP7307817B2 (ja) * 2019-05-06 2023-07-12 メッドシャイン ディスカバリー インコーポレイテッド ｍＴＯＲＣ１／２デュアルキナーゼ活性阻害剤の塩形、結晶形及びその製造方法
WO2021133509A1 (en) * 2019-12-27 2021-07-01 Angex Pharmaceutical, Inc. Heterocyclic compounds as mtor inhibitors
CN116322696A (zh) 2020-05-04 2023-06-23 安进公司 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
JP2024506381A (ja) 2021-02-16 2024-02-13 ヴァクシテック ノース アメリカ， インコーポレイテッド 両親媒性ペプチドに基づく自己集合ナノ粒子
EP4334295A2 (en) * 2021-05-04 2024-03-13 Vigil Neuoscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2023107592A1 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Pyridopyrimidines and methods of their use
WO2024092030A1 (en) 2022-10-25 2024-05-02 Vaccitech North America, Inc. Self-assembling nanoparticles

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4832899A (pl) 1971-08-28 1973-05-02
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
ES2191752T3 (es) 1995-05-10 2003-09-16 Nintendo Co Ltd Sistema de proceso de imagenes utilizando una palanca de mando analogica.
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) * 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
KR100489174B1 (ko) * 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US20020192228A1 (en) * 1997-02-12 2002-12-19 Samir M. Hanash Protein markers for lung cancer and use thereof
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
GB9900334D0 (en) * 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PL199802B1 (pl) * 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
PT1481970E (pt) * 1999-09-07 2006-07-31 Syngenta Participations Ag Novos herbicidas
EP1676845B1 (en) 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
JP4186355B2 (ja) * 1999-11-24 2008-11-26 株式会社デンソー Ｃｓｍａ方式対応無線ｌａｎ用アンテナ装置及び端末局
ES2290117T3 (es) * 2000-02-15 2008-02-16 Sugen, Inc. Inhibidores de proteina quinasa 2-indolina sustituida con pirrol.
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
IL152682A0 (en) * 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
JP4859460B2 (ja) 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
CA2524221A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
WO2007042554A2 (en) * 2005-10-12 2007-04-19 Cancer Research Technology Ltd. Methods and compositions for treating immune disorders
CA2599320A1 (en) * 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
CA2599212A1 (en) * 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
CA2612788A1 (en) 2005-06-24 2006-12-28 Steven Cesar Alfons De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
NZ563639A (en) 2005-06-29 2009-12-24 Compumedics Ltd Sensor assembly with conductive bridge
PL1954699T3 (pl) 2005-11-22 2013-01-31 Kudos Pharm Ltd Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
RS55881B1 (sr) * 2006-08-23 2017-08-31 Kudos Pharm Ltd 2-metilmorfolin pirido-,pirazo- i pirimido-pirimidin derivati kao inhibitori mtor-a

Also Published As

Publication number Publication date
NO20090443L (no) 2009-03-27
WO2008023161A1 (en) 2008-02-28
SA07280461B1 (ar) 2012-04-07
RU2009110261A (ru) 2010-09-27
PT2057156T (pt) 2017-05-04
US20120142673A1 (en) 2012-06-07
DK2057156T3 (en) 2017-05-08
BRPI0715888B1 (pt) 2021-11-03
NO342383B1 (no) 2018-05-14
JP5629343B2 (ja) 2014-11-19
LT2057156T (lt) 2017-05-25
US9717736B2 (en) 2017-08-01
AU2007287430A1 (en) 2008-02-28
US20140135315A1 (en) 2014-05-15
CA2659851C (en) 2014-02-25
US20160067258A1 (en) 2016-03-10
US20170281637A1 (en) 2017-10-05
BRPI0715888A2 (pt) 2013-09-17
SI2057156T1 (sl) 2017-06-30
AR062503A1 (es) 2008-11-12
MY148688A (en) 2013-05-31
KR101438245B1 (ko) 2014-09-04
CL2007002448A1 (es) 2008-05-16
RU2445312C2 (ru) 2012-03-20
BRPI0715888A8 (pt) 2018-04-17
JP2013107915A (ja) 2013-06-06
CY1119381T1 (el) 2018-02-14
US9102670B2 (en) 2015-08-11
CA2659851A1 (en) 2008-02-28
US8101602B2 (en) 2012-01-24
US7902189B2 (en) 2011-03-08
KR20090042855A (ko) 2009-04-30
TW200817395A (en) 2008-04-16
IL196775A0 (en) 2009-11-18
JP2010501535A (ja) 2010-01-21
US20110124638A1 (en) 2011-05-26
RS55881B1 (sr) 2017-08-31
US20080081809A1 (en) 2008-04-03
JP5227321B2 (ja) 2013-07-03
IL196775A (en) 2017-05-29
HUE033894T2 (en) 2018-01-29
AU2007287430B2 (en) 2011-07-21
ES2648388T3 (es) 2018-01-02
CO6150164A2 (es) 2010-04-20
NZ575672A (en) 2011-10-28
TWI406863B (zh) 2013-09-01
MX2009001946A (es) 2009-03-05
US8435985B2 (en) 2013-05-07
US10034884B2 (en) 2018-07-31
HRP20170627T1 (hr) 2017-06-30
EP2057156A1 (en) 2009-05-13
EP2057156B1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
RS55881B1 (sr) 2-metilmorfolin pirido-,pirazo- i pirimido-pirimidin derivati kao inhibitori mtor-a
HK1124039A1 (en) PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
ZA200900992B (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
ZA200807457B (en) Pyrrolidine derivatives as ERK inhibitors
EP2078001B8 (en) Diazepane-acetamide derivatives as selective 11 -hsd1 inhibitors
ZA200807447B (en) Thieno-Pyridine derivatives as MEK inhibitors
PT2094263E (pt) Derivados da 2-adamantil-butiramida como inibidores seletivos da 11-beta-hsd1
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
HK1107348A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
HK1139137A1 (en) Acylaminopyrazoles as fgfr inhibitors
EP2217590A4 (en) Pyridopyrimidine derivatives as PI3-kinase inhibitors
EP2015745A4 (en) MACROCYCLIC KINASE INHIBITORS
HK1134298A1 (en) Substituted estratrien derivatives as 17beta hsd inhibitors 17hsd
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
ZA200804104B (en) Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
IL196807A0 (en) Inhibitors for glyt-1
ZA200809113B (en) Pyrimidine derivatives as p13k inhibitors
ME01487B (me) PIRIDO-,PIRAZO-I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI